When Does Eli Lilly Report Earnings? August 5 Before the Open, With an FDA Decision the Same Day

TL;DR

• Eli Lilly reports Q2 2026 before the US open on Wednesday, August 5, with the conference call at 10:00am ET.
• Consensus sits near $6.00 in EPS, though surveys diverge unusually widely, with some carrying $6.55. It is the largest healthcare report of the month by market value.
• Lilly is the rare megacap growth story with nothing to do with AI capex, which makes it a genuine diversifier in a tape driven entirely by one argument.
• It reports into a crowded Wednesday: Uber also reports before the open, Disney reports before the open, and ADP and ISM services both land.
• The same day carries an FDA decision on Moderna's flu vaccine, making August 5 the densest healthcare day of the quarter.

When Does Eli Lilly Report Earnings?

The short answer: before the US market opens on Wednesday, August 5, 2026, with the earnings call at 10:00am ET.

That is 3:00pm BST in the UK and 10:00pm in Singapore.

Reporting before the open matters mechanically. There is no after-hours drift to watch and no overnight window to reconsider. The gap happens at 9:30am, spreads are wide in the first minutes, and the price you see at 9:31am is frequently not the price the market settles on by 11am.

What the Street Expects

Line	Q2 2026
EPS consensus	~$6.00, with some surveys at $6.55
Report time	Before the open, Wednesday August 5
Conference call	10:00am ET

The headline number is not really the event. Lilly is valued on the trajectory of its obesity and diabetes franchise, and on manufacturing capacity to meet it. A quarter that beats on EPS while flagging supply constraints is a worse outcome than an in-line quarter with capacity expanding.

The Board

The largest healthcare print of the month, on the most crowded day of the week.

Why This One Is Different From Everything Else in August

Every other major report this month is, directly or indirectly, a referendum on AI spending. AMD sells the compute. Palantir sells the software. The hyperscalers buy both.

Lilly is none of that. Its growth depends on drug demand, manufacturing capacity and regulatory outcomes, none of which correlate with what Microsoft spends on data centres. In a market where a bear steepener in long yields is repricing every high-multiple stock at once, an uncorrelated growth story has scarcity value.

That cuts both ways. It also means Lilly gets no lift from an AI relief rally, and it will not be rescued by a strong AMD print the evening before.

The Three Things That Decide It

• Volume growth versus price. For the obesity franchise, growth driven by more prescriptions is worth far more than growth driven by pricing, because pricing is the thing competitors and payers attack first.
• Manufacturing capacity. The constraint on this franchise has been supply, not demand. Any commentary on capacity coming online is a direct read on future revenue.
• The full-year guide. As with every print this season, the forward number sets the reaction. Apple set a company-record gross margin and still fell about 8% because the next quarter's guide came in light.

The Options Angle

• A pre-open report changes the mechanics entirely. There is no after-hours session to watch the reaction develop, so weekly options reprice instantly at 9:30am with wide spreads. Execution risk in the first minutes is real and it is expensive.
• Because of that gap risk, defined-risk structures beat naked positions here more than in an after-hours reporter. You cannot manage a position that gaps through your strike before you can trade it.
• Lilly's share price makes single contracts large in notional terms. That removes several strategies from smaller accounts entirely, which is the same practical constraint that applies to any high-priced stock.
• For long-term holders, a covered call into the pre-earnings volatility bid is reasonable, but keep strikes generous: this is a franchise that has repeatedly produced sustained moves rather than one-day pops.

The One-Line Read

Eli Lilly reports before the open on Wednesday August 5 with the call at 10:00am ET and consensus near $6.00 on a notably wide spread of estimates, on the most crowded day of the month alongside Uber, Disney, ADP, ISM services and an FDA decision: it is the one large report in August with nothing to do with AI capex, which makes it both a genuine diversifier and a stock that gets no help from the argument driving everything else, and the lines that matter are volume growth and manufacturing capacity rather than the EPS headline.